Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that is responsible for several cutaneous side effects. We report a case of hand-foot syndrome associated with a papulo-pustular and seborrheic dermatitis-like eruption of the face in a 61-year-old patient treated with erlotinib for lung cancer.
Benomar
Sophia
S
Department of dermatology, Ibn Sina Hospital, Mohamed V University of Rabat, Morocco. sophiabenomar@yahoo.fr
Boutayeb
Saber
S
Afifi
Yassir
Y
Hamada
Syrine
S
Bouhllab
Jamila
J
Hassam
Badreddine
B
Errihanni
Hassan
H
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D012628:Dermatitis, Seborrheic / Q000139:chemically induced* / Q000503:physiopathology; D018450:Disease Progression; D003875:Drug Eruptions / Q000209:etiology* / Q000503:physiopathology; D000069347:Erlotinib Hydrochloride; D005148:Facial Dermatoses / Q000139:chemically induced / Q000503:physiopathology; D005500:Follow-Up Studies; D006229:Hand Dermatoses / Q000139:chemically induced / Q000503:physiopathology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D013577:Syndrome
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride